From Podium To Practice – Breast Cancer ESMO Part 4
In this overview, Dr. Wassim Mchayleh breaks down the evERA trial, which evaluates elacestrant-based combination strategies for ER-positive/HER2-negative metastatic breast cancer, with a focus on ESR1-mutated disease. He reviews the trial’s design, goals, and emerging efficacy signals, emphasizing the ongoing need to optimize endocrine-based therapy as resistance develops.